Low-dose aspirin for protecting kidneys in early diabetic nephropathy
Treatments studied
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This trial studies whether a low daily dose of aspirin can help protect kidney function in people with early diabetic nephropathy. It aims to slow down the progression of kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have diabetic nephropathy (kidney damage from diabetes). This can be shown by certain lab results (like protein in the urine) or a kidney biopsy.
- Your kidney function (eGFR) must be above 30 — this means your kidneys are still working at least a moderate level.
- You must not have had a heart attack, stroke, or other serious blood vessel event in the past.
- You must not have a history of stomach ulcers, bleeding in the brain, or other major bleeding.
- You must not be taking blood-thinning medications (like warfarin or clopidogrel) or certain pain relievers (like ibuprofen).
- You must not be pregnant or have a known allergy to aspirin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial focuses on improving how kidney damage is diagnosed and how treatment is planned for people with type 2 diabetes and kidney disease. It may help by using detailed medical history and (if done) kidney biopsy results to guide care more accurately.
This early-stage study tests how a daily aspirin tablet behaves in the body and how it affects blood/clotting markers in people with type 2 diabetes. It may help researchers understand whether this form of aspirin could be useful, especially if you’re not currently taking aspirin.
This Phase 3 study tests whether colchicine and a special type of aspirin can lower the risk of future heart attacks, strokes, or other major heart problems in people with type 2 diabetes who have not had a prior heart event. It aims to reduce cardiovascular risk using medicines that may calm inflammation and protect blood vessels.
This Phase 2 study tests whether adding NAD can improve kidney health in people with diabetes-related kidney disease. It is designed for people with certain urine lab results showing kidney stress, while keeping blood sugar and safety limits within range.
This study tests whether a goal-directed treatment plan using several medications can lower the risk of kidney and heart problems for people with diabetes and kidney disease. It aims to help you manage your condition more effectively.
This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.
Hear when a new Diabetic Nephropathy Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.